In general, children who have been fully vaccinated before there is evidence of immunocompromisation should be tested for vaccine antibody levels LDK378 in vitro when primary vaccination and booster doses have been completed, i.e. at around 4–6 years of age. Those who were vaccinated when they had any degree of immunosuppression should have specific immunity re-checked after approximately 5 years (at age 9–11 years) and again 5 years later, before transfer to adult care (at age 14–16 years). Accepted

cut-off protective titres for vaccine-preventable diseases [40, 106-113] are suggested (Table 3), acknowledging that the evidence base is limited in some areas. Assays that meaningfully reflect the level of individual protection are not routinely available for all vaccines and, when available, defined levels of protection may not be relevant to HIV-positive individuals. > 10 IU/L protective > 100 IU/L optimal A further challenge is how to vaccinate those children whose vaccine status is unknown or incomplete, including

children from other countries. Unless a reliable vaccine history is available, individuals should be assumed to be unimmunized and a full course of immunization should BTK inhibitor mouse be planned. In the absence of vaccination details, serology provides partial guidance on their immunization status but prevents assessment of the durability of seroprotection or the capacity for anamnestic responses. The following guidance addresses catch-up immunization priories. HBV: measure serology

and offer a complete series to susceptible children (three doses), ideally using combined HAV and HBV vaccine. Figure 1 is an algorithm for immunizing HIV-infected children with uncertain or incomplete immunization Cediranib (AZD2171) status; this schedule is based on the routine vaccine schedule and formulations currently available in the UK and on guidance provided by the UK Health Protection Agency. The schedule can be modified according to local schedules and availability. It should be noted (as discussed in section 5) that the use of PPV23 is controversial and is not included in this guidance. PCV should be considered for previously unimmunized children over 5 years of age, ensuring that 2 doses are given at least 2 months apart. Even after normalization of the CD4 cell count on HAART, vaccine responsiveness may be inadequate because of pre-existing and irreversible immune impairment, given that responsiveness to vaccination is related to the nadir CD4 cell count for some vaccines [114]. Moreover, impaired B-cell memory responses persist despite effective HAART [115, 116]. A suboptimal response to primary vaccinations and a requirement for additional reinforcing doses of vaccine should be anticipated and, if the patient was severely immunocompromised when primary vaccination courses were administered, then complete revaccination after immune recovery on HAART should be the standard of care.